AMD
Conditions
Keywords
Age-related macular degeneration,laser flare photometry, anti-VEGF, aflibercept, brolucizumab,exudative
Brief summary
To evaluate the status of the blood-aqueous barrier by objectively measuring protein concentration in the aqueous humor using laser flare photometry (LFP) in patients with exudative age-related macular degeneration (AMD) undergoing anti-angiogenic therapy.
Detailed description
All patients were assigned to two groups. The first group was administered intravitreal injections of 2 mg (0.05 mL) aflibercept, while the second group received 6 mg (0.05 mL) brolucizumab. The regimen of treatment in both groups was treat-and-extend
Interventions
DIAGNOSTIC_TESTlaser flare photometry before intravitreal injection
The first group was administered intravitreal injections of 2 mg (0.05 mL) aflibercept The second group received 6 mg (0.05 mL) brolucizumab. Objectively measuring protein concentration in the aqueous humor using laser flare photometry (LFP).
Sponsors
The Filatov Institute of Eye Diseases and Tissue Therapy
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
47 Years to 88 Years
Healthy volunteers
No
Inclusion criteria
only primary, untreated patients with exudative AMD who were eligible for anti-VEGF therapy were included in the study. -
Exclusion criteria
patients with hyperlipidemia, cardiac or renal insufficiency, ocular neoplasms, glaucoma, as well as those with corneal opacity within the optical zone or any inflammation of the studied eye that could lead to increased light-scattering intensity of protein molecules in the anterior chamber fluid, as measured by laser flare photometry, were excluded from the study. \-
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| laser flare photometry values in the aqueous humor | 6-month | Detection of protein concentration in the aqueous humor using laser flare photometry |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| best-corrected visual acuity | 6-month | the change in best-corrected visual acuity (BCVA) |
| central retinal thickness | 6-month | central retinal thickness (CRT) |
Countries
Ukraine
Contacts
PRINCIPAL_INVESTIGATORAndrii MD Korol, PhD
The Filatov Institute of Eye Diseases and Tissue Therapy
Outcome results
None listed